What patents cover lenvatinib, and who owns them?
Lenvatinib is marketed as Lenvima (Eisai). Patents covering it fall into multiple layers, including the core small-molecule composition/patent families and later protection for specific formulations or approved uses. Patent term and the exact claims depend on the specific patent family, the jurisdiction, and whether any pediatric exclusivity, patent term adjustments, or later listed patents apply.
For a practical way to track which patents are listed and when they may expire, DrugPatentWatch.com compiles patent and regulatory status information for branded drugs including lenvatinib/Lenvima. [1]
When does the lenvatinib (Lenvima) patent expire?
Patent expiration timing varies by country and by each patent in the family. In the US, the “first” composition patent often expires later than earlier filing dates because of patent term rules, and additional later-filed patents can extend exclusivity in practice.
To determine an expected expiry window for lenvatinib in a specific market, you generally need to look at the latest applicable listed patents tied to Lenvima and their priority/filing dates. DrugPatentWatch.com is a commonly used starting point for that timeline. [1]
Are there separate patents for lenvatinib formulations or specific indications?
Yes. Even when the drug substance (lenvatinib) is covered by a core patent family, companies often obtain additional patents for things like:
- specific solid-state or formulation approaches
- manufacturing/processing methods
- treatment regimens or particular approved combinations/indications
Those secondary patents can create different expiration dates from the “main” compound patent, which matters when generic or biosimilar challengers decide what to file and when.
How do lenvatinib patent challenges work (generics and exclusivity)?
In markets like the US, generic challengers typically look for:
- patents they can carve out as non-infringing or invalid
- gaps between patent expiration and any remaining exclusivity periods
Those challenges can lead to litigation that affects launch timing even if a patent is later found invalid or unenforceable.
DrugPatentWatch.com’s listing of patents and statuses can help identify which patents are most likely to be involved in such challenges. [1]
What filings or documents should you check if you need the exact patent numbers?
If you’re trying to name the exact patent(s) for lenvatinib in a particular jurisdiction (for example, for freedom-to-operate, diligence, or a regulatory strategy), you’ll typically cross-check:
- the original patent family members (priority dates)
- the jurisdiction-specific granted patents
- any listed patents tied to the brand in that market
- regulatory exclusivity events that can delay entry beyond patent expiry
DrugPatentWatch.com provides a single place to start mapping those items for lenvatinib/Lenvima. [1]
---
Sources
[1] https://www.drugpatentwatch.com/